Additionally, no immune-related adverse effects were observed.[71] In several tumor models, specifically advanced melanoma, the simultaneous inhibition of LAG-3 and PD-1 demonstrates a more significant antitumor effect when compared to the use of individual McAbs.[71–74] The combination of Nivolumab with Relatlimab has shown significant advantages compared to Nivolumab monotherapy in a phase II/III clinical trial.[75]. The gene discussed is LAG3; the disease is neoplasm.